Transitional Cell Carcinoma — Trials

Transitional Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

734 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 253
Recruiting: 125
Ph III recruiting: 17
Growth YoY: +47.5%
Industry share: 31%
Top sponsor: National Cancer Institute (NCI)
Termination share: 44%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (119)

clinicaltrialsPublishedShowing 1–7 of 7 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07217496	N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer	not yet recruiting	Phase 1	18	ImmunityBio, Inc.INDUSTRY	1	Sep 24, 2026	clinicaltrials
NCT07807345	Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic	not yet recruiting	Phase 1	285	Sutro Biopharma, Inc.INDUSTRY	1	Sep 8, 2026	clinicaltrials